Aridis Pharmaceuticals, Inc. (ARDS) has an overall financial health rating of C- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-08-20.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-08-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-12 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-08 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-07-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
